Perpetual Ltd acquired a new position in Insulet Corporation (NASDAQ:PODD - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 11,795 shares of the medical instruments supplier's stock, valued at approximately $3,097,000.
A number of other large investors have also recently made changes to their positions in PODD. SBI Securities Co. Ltd. purchased a new stake in Insulet during the fourth quarter valued at approximately $36,000. Arrowstreet Capital Limited Partnership bought a new stake in Insulet in the fourth quarter worth $9,822,000. Farther Finance Advisors LLC boosted its stake in Insulet by 85.1% during the first quarter. Farther Finance Advisors LLC now owns 896 shares of the medical instruments supplier's stock worth $236,000 after buying an additional 412 shares during the period. Exchange Traded Concepts LLC raised its stake in shares of Insulet by 225.4% in the first quarter. Exchange Traded Concepts LLC now owns 1,552 shares of the medical instruments supplier's stock valued at $408,000 after acquiring an additional 1,075 shares during the period. Finally, QRG Capital Management Inc. lifted its holdings in shares of Insulet by 75.6% in the 1st quarter. QRG Capital Management Inc. now owns 2,030 shares of the medical instruments supplier's stock worth $533,000 after acquiring an additional 874 shares during the last quarter.
Insulet Stock Performance
PODD traded up $3.25 on Friday, reaching $313.08. 760,290 shares of the stock were exchanged, compared to its average volume of 713,879. The company's 50-day moving average price is $297.69 and its 200 day moving average price is $277.64. The company has a debt-to-equity ratio of 1.21, a current ratio of 4.47 and a quick ratio of 3.63. The firm has a market capitalization of $22.03 billion, a PE ratio of 56.31, a PEG ratio of 2.79 and a beta of 1.37. Insulet Corporation has a fifty-two week low of $173.00 and a fifty-two week high of $329.33.
Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, beating the consensus estimate of $0.81 by $0.21. The business had revenue of $569.00 million during the quarter, compared to analysts' expectations of $543.20 million. Insulet had a net margin of 18.29% and a return on equity of 22.25%. The business's quarterly revenue was up 28.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.73 EPS. As a group, sell-side analysts forecast that Insulet Corporation will post 3.92 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research analysts have issued reports on PODD shares. Raymond James Financial restated an "outperform" rating and set a $360.00 target price (up previously from $328.00) on shares of Insulet in a research report on Tuesday, May 27th. The Goldman Sachs Group began coverage on shares of Insulet in a research note on Friday, May 30th. They issued a "buy" rating and a $380.00 price target on the stock. Truist Financial assumed coverage on shares of Insulet in a research report on Monday, June 16th. They set a "buy" rating and a $365.00 target price on the stock. Citigroup reaffirmed a "buy" rating and set a $380.00 target price (up from $320.00) on shares of Insulet in a research report on Thursday, May 22nd. Finally, Wall Street Zen downgraded Insulet from a "buy" rating to a "hold" rating in a report on Saturday, June 14th. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $321.00.
Read Our Latest Report on Insulet
Insider Buying and Selling at Insulet
In other Insulet news, SVP John W. Kapples sold 5,278 shares of the company's stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the transaction, the senior vice president now owns 23,180 shares in the company, valued at approximately $7,382,134.60. This represents a 18.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.39% of the company's stock.
About Insulet
(
Free Report)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
Featured Articles
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
